Report Categories
View AllRecent Articles
View All
Is Coherus CHRS stock losing upward momentum Bullish Sentiment 20260420
Regeneron Pharmaceuticals REGN Secures Dupixent Pediatric EU Approval Enters Radiopharmaceuticals Via Telix Collaboration
Goosehead Insurance GSHD Stock Is It Worth Your Money Institutional Demand 20260420
CRWV CoreWeave shares climb 641 on 1679 yearoveryear revenue growth despite larger than expected quarterly loss
Alliance Ent AENTW warrants draw attention as investors await quarterly results amid limited financial disclosures
Sebi Uncovers PumpandDump Scheme Across 82 SME Stocks Rs 2025 Crore Impounded
Swiss Franc and Japanese Yen Strengthen as DeepSeeks AI Model Sparks SafeHaven Demand
SpaceX Delays Starship Flight 12 to Friday Debuting V3 Rocket with Enhanced Capacity
Smart Glasses Sales Surge Amid Privacy Debates Meta Leads Growth
Asias Currencies Under Pressure as Oil Prices Surge and US Dollar Strengthens Amid Iran Tensions
Japans Megabanks Report Record Profits But Analysts Warn of Potential Growth Slowdown Amid Rising Risks
MSA Q1 2026 Earnings EPS Beat Leads to Modest Share Price Gain
MCFT Q1 2026 Earnings EPS Surges Past Estimates
Crane Company CR Q1 2026 Earnings EPS Surpasses Estimates by 106 Shares Edge Higher
CPF Q1 2026 Earnings EPS Beats Estimates by 44 Amid Solid Operating Performance
CXAI Q4 2025 Earnings EPS Misses Estimates Stock Declines 9
Bayview Acquisition Corp BAYA Plunges 565 as SPAC Premium Shrinks Amid Deal Uncertainty
Casella Waste Systems Holds Near Support After Slight Uptick
CF Financial Corporation CFFI Edges Higher as Stock Holds Above Key Support Level
Eaton Vance Municipal Income 2028 Term Trust ETX Holds Steady Near 191 Amid Modest Uptick
Electrovaya ELVA Climbs 8 Support and Resistance in Focus
Adeia Inc ADEA Advances 19 as Support Holds and Resistance Nears
Chevron CVX Holds Steady Near Key Resistance Levels Amid Modest Gains
Infinite Eagle Acquisition Corp Unit IEAGU Holds Steady at 1020 Amid Quiet Trading
1RT Acquisition Corp ONCH Holds Steady Near Resistance RangeBound Action Continues
Chemomab Therapeutics CMMB Stages a Sharp Rebound Can the Biotech Sustain Its Upward Momentum